317 related articles for article (PubMed ID: 11706392)
1. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
Schneider JW; Chang AY; Garratt A
Semin Oncol; 2002 Jun; 29(3 Suppl 11):22-8. PubMed ID: 12138394
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
[TBL] [Abstract][Full Text] [Related]
4. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
[TBL] [Abstract][Full Text] [Related]
5. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Perez EA
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
[TBL] [Abstract][Full Text] [Related]
6. Cancer therapy-associated cardiotoxicity and signaling in the myocardium.
Zuppinger C; Suter TM
J Cardiovasc Pharmacol; 2010 Aug; 56(2):141-6. PubMed ID: 20386457
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
Leemasawat K; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Cell Mol Life Sci; 2020 Apr; 77(8):1571-1589. PubMed ID: 31650186
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
[TBL] [Abstract][Full Text] [Related]
10. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.
Eldridge S; Guo L; Mussio J; Furniss M; Hamre J; Davis M
Toxicol Sci; 2014 Oct; 141(2):547-59. PubMed ID: 25055963
[TBL] [Abstract][Full Text] [Related]
11. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
[TBL] [Abstract][Full Text] [Related]
12. Herceptin and the heart--a molecular modifier of cardiac failure.
Chien KR
N Engl J Med; 2006 Feb; 354(8):789-90. PubMed ID: 16495390
[No Abstract] [Full Text] [Related]
13. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
[TBL] [Abstract][Full Text] [Related]
14. Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.
Seemann I; te Poele JA; Song JY; Hoving S; Russell NS; Stewart FA
Breast Cancer Res Treat; 2013 Oct; 141(3):385-95. PubMed ID: 24091769
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
16. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.
Chien KR
Semin Oncol; 2000 Dec; 27(6 Suppl 11):9-14; discussion 92-100. PubMed ID: 11236034
[TBL] [Abstract][Full Text] [Related]
17. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.
Horie T; Ono K; Nishi H; Nagao K; Kinoshita M; Watanabe S; Kuwabara Y; Nakashima Y; Takanabe-Mori R; Nishi E; Hasegawa K; Kita T; Kimura T
Cardiovasc Res; 2010 Sep; 87(4):656-64. PubMed ID: 20495188
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity profile of trastuzumab.
Ewer SM; Ewer MS
Drug Saf; 2008; 31(6):459-67. PubMed ID: 18484781
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab--mechanism of action and use in clinical practice.
Hudis CA
N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
[No Abstract] [Full Text] [Related]
20. PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications.
Xu Z; Gao Z; Fu H; Zeng Y; Jin Y; Xu B; Zhang Y; Pan Z; Chen X; Zhang X; Wang X; Yan H; Yang X; Yang B; He Q; Luo P
Cardiovasc Res; 2023 May; 119(5):1250-1264. PubMed ID: 36651911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
